About
Prism BioLab develops proprietary small-molecule peptidomimetics called PepMetics® designed to target previously undruggable protein-protein interactions, focusing on indications like oncology, cirrhosis, and gastrointestinal disorders, with licensed programs such as PRI724 and E7386.
Explore Prism BioLab's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.